Philip Helliwell
Overview
Explore the profile of Philip Helliwell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
86
Citations
2808
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Adebajo A, Sommerlad M, Savage L, Helliwell P
Rheumatology (Oxford)
. 2025 Mar;
PMID: 40036756
No abstract available.
2.
Winter E, Dekkers O, Andreasen C, DAngelo S, Appelman-Dijkstra N, Appenzeller S, et al.
Ann Rheum Dis
. 2025 Feb;
84(2):169-187.
PMID: 39919892
Background: There is considerable practice variation in labelling, diagnosis and treatment of adults with sterile bone inflammation. We developed a expert consensus recommendations on the disease definition, diagnosis and treatment...
3.
James L, Hailey L, Bundy C, Burstow H, Chandler D, Cowper R, et al.
Rheumatology (Oxford)
. 2024 Dec;
PMID: 39705200
Objectives: Little is known about the ideal service delivery model and shortcomings in patient experiences in the NHS for patients with Psoriatic Arthritis (PsA). To identify unmet needs perceived within...
4.
McHugh N, Tillett W, Helliwell P, Packham J, Collier H, Davies C, et al.
Rheumatology (Oxford)
. 2024 Jul;
PMID: 39037920
Background: Our objective was to determine whether early detection of undiagnosed psoriatic arthritis (PsA) in a primary care psoriasis population improves outcome in physical function at 24 months post-registration. Methods:...
5.
Hen O, Di Matteo A, Dubash S, De Marco G, Tan A, Emery P, et al.
RMD Open
. 2024 Apr;
10(2).
PMID: 38580344
Aims: To investigate the prevalence and distribution of bone erosions in an early psoriatic arthritis (PsA) population using conventional radiography (CR) and to explore the agreement between CR and ultrasound...
6.
De Lorenzis E, Kakkar V, Di Donato S, Wilson M, Barnes T, Denton C, et al.
RMD Open
. 2024 Jan;
10(1).
PMID: 38216288
Background: Hand involvement is an early manifestation of systemic sclerosis (SSc), culprit of diagnosis and classification, and recognised major driver of disability. Impairment of hand function burdens both limited and...
7.
Coyle C, Watson L, Whately-Smith C, Brooke M, Kiltz U, Lubrano E, et al.
Rheumatology (Oxford)
. 2024 Jan;
64(1):242-251.
PMID: 38191998
Objectives: The AsseSSing Impact in pSoriatic Treatment (ASSIST) study investigated prescribing in routine PsA care and whether the patient-reported outcome-PsA Impact of Disease questionnaire (PsAID-12)-impacted treatment. This study also assessed...
8.
Watson L, Coyle C, Whately-Smith C, Brooke M, Kiltz U, Lubrano E, et al.
Rheumatology (Oxford)
. 2023 Nov;
63(12):3449-3456.
PMID: 38011669
Objectives: Shared decision-making (SDM) is advocated to improve patient outcomes in PsA. We analysed current prescribing practices and the extent of SDM in PsA across Europe. Methods: The ASSIST study...
9.
Dand N, Stuart P, Bowes J, Ellinghaus D, Nititham J, Saklatvala J, et al.
medRxiv
. 2023 Oct;
PMID: 37873414
Psoriasis is a common, debilitating immune-mediated skin disease. Genetic studies have identified biological mechanisms of psoriasis risk, including those targeted by effective therapies. However, the genetic liability to psoriasis is...
10.
Mease P, Helliwell P, Silwinska-Stanczyk P, Miakisz M, Ostor A, Peeva E, et al.
Arthritis Rheumatol
. 2023 May;
75(8):1370-1380.
PMID: 37194394
Objective: Brepocitinib is a TYK2/JAK1 inhibitor in development for the treatment of several immunologic diseases. The efficacy and safety of oral brepocitinib were assessed in participants with moderately-to-severely active psoriatic...